Podcasts about Lymphoma

In this Review Series episode, Associate Editor Dr. Philippe Armand speaks with multiple authors about what it might look like to improve treatments follicular lymphoma, a disease that has been put on the backburner of innovation due to its generally treatable nature. Dr. Armand discusses "Treatment of relapsed and refractory follicular lymphoma: which treatment for which patient for which line of therapy?" with author Dr. Carla Casulo,  "The future of follicular lymphoma management: strategies on the horizon” with author Dr. Sarah C. Rutherford, and "An updated understanding of follicular lymphoma transformation” with Dr. Erin M. Parry.Find the whole review series on follicular lymphoma in volume 146 issue 15 of Blood Journal.  

Evening prayer (renew us, O Lord, people with lymphoma) #prayer #pray #eveningprayer #jesus #god #holyspirit #aimingforjesus #healing #bible #love #peace #lymphoma #nonhodgkinslymphoma #hodkinslymphoma #renew Thank you for listening, our heart's prayer is for you and I to walk daily with Jesus, our joy and peace aimingforjesus.com YouTube Channel https://www.youtube.com/@aimingforjesus5346 Instagram https://www.instagram.com/aiming_for_jesus/ Threads https://www.threads.com/@aiming_for_jesus X https://x.com/AimingForJesus Tik Tok https://www.tiktok.com/@aiming.for.jesus

Hosts Mike Guidone and Chris Caputo welcome Conner Clark to the show to talk top 25 college football. Later, AJ Rovner called in to discuss the good and bad of the Giants game in Denver. Finally, University of Maine punter and native Long Islander Anthony Pecorella discussed his collegiate career and triumph over Lymphoma.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Michael Wang, MD For patients with mantle cell lymphoma (MCL) who relapse after BTK inhibitor (BTKi) therapy, treatment decisions can be complex and time sensitive. That's why understanding how tumor biology and risk features can guide selection between immunomodulatory regimens and CAR T-cell therapy is essential. Tune in to hear Dr. Charles Turck speak with Dr. Michael Wang about practical, evidence-based strategies for managing relapsed/refractory MCL. Dr. Wang is a Professor in the Department of Lymphoma and Myeloma in the Department of Stem Cell Transplantation at MD Anderson Cancer Center in Houston, Texas.

In this week's episode of the Blood Podcast, Associate Editor Dr. James Griffin interviews Drs. Binod Dhakal and Ruben Bierings about their respective papers published in this week's issue of Blood. Dr. Dhakal presents his study on using talquetamab, a bispecific antibody, as a bridging therapy before BCMA-targeted CAR T-cell therapy in multiple myeloma patients, showing promising results with high response rates and manageable toxicities. Next, Dr. Bierings identified patients with genetic variants in the guanine exchange factor MAP kinase–activating death domain (MADD) that impair VWF secretion from endothelial cells and possibly cause VWD type 1. Featured ArticlesA novel cause of type 1 von Willebrand disease: impaired exocytosis of Weibel-Palade bodies due to biallelic MADD variantsSophie Hordijk, Stijn A. Groten, Petra E. Bürgisser, Sebastiaan N. J. Laan, Georg Christoph Korenke, Tomáš Honzík, Diane Beysen, Frank W. G. Leebeek, Paul A. Skehel, Maartje van den Biggelaar, Tom Carter, Ruben BieringsSequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapyBinod Dhakal, Othman S. Akhtar, David Fandrei, Alexandria Jensen, Rahul Banerjee, Darren Pan, Shambavi Richard, Reed Friend, Matthew Rees, Patrick Costello, Mariola Vazquez Martinez, Oren Pasvolsky, Charlotte Wagner, James A. Davis, Omar Castaneda Puglianini, Ran Reshef, Aimaz Afrough, Danai Dima, Manisha Bhutani, Omar Nadeem, Ricardo Parrondo, Ciara Freeman, Lekha Mikkilineni, Shahzad Raza, Larry D. Anderson Jr, Prashant Kapoor, Hitomi Hosoya, Saurabh Chhabra, Ariel Grajales-Cruz, Mahmoud Gaballa, Shonali Midha, Melissa Alsina, Douglas Sborov, Krina Patel, Yi Lin, Christopher Ferreri, Nico Gagelmann, Anupama Kumar, Doris Hansen, Andrew Cowan, Luciano J. Costa, Maximilian Merz, Surbhi Sidana

In this Spotlight series episode on Acute Myeloid Leukemia, Blood Editor, Dr. Selina Luger interviews Drs. Laura Michaelis and Alexander Perl on their paper in the series titled “The fit older adult with acute myeloid leukemia: clinical challenges to providing evidence-based frontline treatment”. The conversation explores challenges in treating AML across different patient populations. They also focus on treatment approaches for fit older adults with AML, highlighting the need for less toxic therapies and ongoing randomized trials to better understand treatment efficacy. See the full spotlight series on Acute Myeloid Leukemia in Volume 145 Issue 24 of Blood journal. 

In this week's episode we'll learn more about a study comparing busulfan-melphalan with melphalan alone as the conditioning protocol for newly diagnosed, transplant-eligible multiple myeloma; then we will discuss data on how three-dimensional transcriptomics can reveal complex interactions between plasma cells and bone marrow microenvironments.Featured ArticlesHigh-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trialProfiling the spatial architecture of multiple myeloma in human bone marrow trephine biopsy specimens with spatial transcriptomicsPreclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma

In this episode, Meghan Gutierrez, CEO of the Lymphoma Research Foundation, shares insights on how proposed NIH budget cuts could impact cancer research, the importance of stable funding for early-career scientists, and how the foundation is supporting innovation and patient education to accelerate progress against lymphoma.

Cortney Campbell was diagnosed with a rare form of Hodgkin's lymphoma in 2008 at age 26. After a PET scan and other testing she learned it was in her neck, opposite armpit, and small amounts in her rib cage. She had a lymph node biopsied and found that the cancer was slow growing but needed to be addressed because of how much it had spread.  Since the suggested conventional treatment threatened her fertility amongst other permanent side effects, she and her husband opted to pursue non-toxic strategies as a Plan A.  After 8 months of specific anti-cancer diet and lifestyle changes, Cortney was NED and has been ever since. She now has 6 children and leads a community of like-minded cancer thrivers Connect with Cortney@anticancermom on IG and Facebook. You can learn more about her story at AnticCancerMom.com. Resources: Healing Strong Bill Henderson Budwig Protocol Anne Wigmore ___________ To learn more about the 10 Radical Remission Healing Factors, connect with a certified RR coach or join a virtual or in-person workshop visit www.radicalremission.com.   To watch Episode 1 of the Radical Remission Docuseries for free, visit our YouTube channel here.  To purchase the full 10-episode Radical Remission Docuseries visit Hay House Online Learning. To learn more about Radical Remission health coaching with Liz or Karla, Click Here Follow us on Social Media: Facebook  Instagram YouTube ____________ Why does Dr. Linda Isaacs, M.D., a board-certified internist, offer an enzyme-based nutritional program for cancer patients? Decades of seeing people have much better outcomes than expected. The approach she uses is not an easy answer and it's not a guarantee. It involves a lot of capsules and big lifestyle changes. But for the right patient, it can be transforming. For more information about her work, please visit her website at www.drlindai.com/radical You can also listen to her interview on the Radical Remission podcast: https://www.podbean.com/ew/pb-7v5kr-1546ad9

Send us a textIn June, the Fatty Liver Foundation officially launched the Stephen A. Harrison Patient Advocacy program and announced its first class of 20 Fellows. In today's conversation, Louise Campbell and Roger Green interview the founders to learn what motivated them to launch this program, and we meet five of the initial Fellows. Program Co-ordinator Elena Samsonova opens the conversation by celebrating last week's onboarding of 20 inaugural Fellows and the chemistry between them. She goes on to introduce five of them:Steven Rodrigues (ALD, UK citizen) shares his recent experience giving a 15-minute national interview on BBC Radio 5 discussing ALD clinical insights. Silvana Lesidrenska (Hepatitis B, Bulgaria) shares her desire to learn more about SLD as part of her advocacy leading a liver patients association in Bulgaria. Julie Peyout (MASH, Canada) is a great-grandmother who was recently found free after therapy for Non-Hodgkin's Lymphoma. Pam Miller (MASH cirrhosis, US) learned 24 years ago that she had MASH cirrhosis when her surgeon aborted a bariatric procedure. Since then, she has lived with cirrhosis and experienced hepatic encephalopathy (HE). She has participated in clinical trials, lobbied legislators, and collaborated with professional societies. Melanie Smith  (MASH cirrhosis, US) has lived with stage-4 MASH cirrhosis since age 36 (sixteen years ago) and experiences hepatic encephalopathy (HE). She has led support groups for over a decade. Next, Fatty Liver Foundation President Wayne Eskridge recounts the program's foundational story. He describes Stephen as a man with a genuine commitment to patients and his passing as a "tremendous loss." This led Wayne to discuss this idea with Rebecca Taub of Madrigal, "another one of my heroes." (Madrigal supports this program.) Elena describes how she joined the FLF to lead this program. Roger asks the Fellows where and how they intend to make a difference. Their goals vary, from working in a Biopharma company advocating for patients to "going to the top," perhaps even lobbying the HHS Secretary, to expanding their own education and knowledge about the various forms of SLD.  

Send us a text00:00:00 - Surf's Up: Season 6 Episode 14Louise Campbell and Roger Green interview key players in the inaugural Dr. Stephen A. Harrison Patient Advocacy Fellowship program, including Wayne Eskridge of the Fatty Liver Foundation (FLF), which initiated the program, Program Coordinator Elena Samsonova, and five Harrison Fellows.00:05:08 - Part I: How the Harrison Fellowship Came To BeElena opens by celebrating last week's onboarding of 20 inaugural Fellows and the chemistry between them. She goes on to introduce five of them:Steven Rodrigues (ALD, UK citizen) shares his recent experience giving a 15-minute national interview on BBC Radio 5 discussing ALD clinical insights. Silvana Lesidrenska (Hepatitis B, Bulgaria) shares her desire to learn more about SLD as part of her advocacy leading a liver patients association in Bulgaria. Julie Peyout (MASH, Canada) is a great-grandmother who was recently found free after therapy for Non-Hodgkin's Lymphoma. Pam Miller (MASH cirrhosis, US) learned 24 years ago that she had MASH cirrhosis when her surgeon aborted a bariatric procedure. Since then, she has lived with cirrhosis and experienced hepatic encephalopathy (HE). She has participated in clinical trials, lobbied legislators, and collaborated with professional societies. Melanie Smith  (MASH cirrhosis, US) has lived with stage-4 MASH cirrhosis since age 36 (sixteen years ago) and experiences hepatic encephalopathy (HE). She has led support groups for over a decade. Next, Wayne recounts the program's foundational story. He describes Stephen as a man with a genuine commitment to patients and his passing as a "tremendous loss." This led Wayne to discuss this idea with Rebecca Taub of Madrigal, "another one of my heroes." (Madrigal supports this program.) Elena describes how she joined the FLF to lead this program. Roger asks the Fellows where and how they intend to make a difference. Their goals vary, from working in a Biopharma company advocating for patients to "going to the top," perhaps even lobbying the HHS Secretary, to expanding their own education and knowledge about the various forms of SLD.  00:34:46 - Part II: Goals of the Harrison Fellowship ProgramThis conversation focuses on the program's goals and scope for its first year. Wayne points out that, while the FLF originally focused on NAFLD and NASH, the new nomenclature has led them to broaden their focus to all forms of SLD. (He plans to rebrand as the Steatotic Liver Foundation.)Elena, it describes the program's four "pillars": Mentorship - Having an experienced advocate guide each Fellow as they pursue the next steps as Advocates.Education - Learning more about SLD.Networking - Connecting with other advocates and industry decision-makers at conferences.Fellowship - Supporting each other as they grow new skills and have new experiences. 00:55:09 - Experts: Louise and Roger Discuss This RoundtableRoger and Louise share their enthusiasm for the unprecedented sense of empowerment they felt among patient advocates while leading this discussion. Both comment on the identity shift from “MASH patient” to “person living with MASH.” Louise mentions that doctors or APPs still minimize disease by characterizing MASLD as “a bit of fat” that requires no action. Roger suggests that focusing on the total patient will include not only the efficacy of medicines but also potential side effects or safety concerns. Louise comments that advanced disease and cirrhosis occur most often in post-menopausal women with cirrhosis, and discusses implications. Both foresee a growing “army” of advocates that can drive earlier detection, smarter trial design, and better everyday care.01:11:11 - Business Report

In this How I Treat podcast episode, Laura Michaelis, MD interviews Sung-Yun Pai, MD about their recently published article in Blood journal "How I treat Wiskott-Alrich syndrome". They highlight recent updates in treatment, including new risk-benefit calculations due to safer treatments and longer follow-ups. Challenges include late diagnosis, lack of well-matched donors, and limited gene therapy availability. They emphasize the importance of early referral to specialized centers and the need for discussions about curative intent therapies, including transplant and gene therapy. The conversation also covers the complexities of gene therapy, such as the need for better conditioning agents and the challenges of achieving full correction in all cell types.

In this week's episode we'll learn about targeting the tissue factor pathway inhibitor with a monoclonal antibody to rebalance HEMOSTASIS in hemophilia A and B. In the phase 3 BASIS trial, the monoclonal antibody marstacimab reduced bleeding events, and was generally well tolerated, with no unanticipated side effects. After that: matched-donor allogeneic CD19 CAR-T for adult B-ALL. Given after allogeneic transplantation, CAR-donor lymphocyte infusion after lymphodepleting chemotherapy was associated with favorable efficacy and a tolerable safety profile. Finally: a new prognostic index for mycosis fungoides and Sézary syndrome. Comprised of four prognostic factors, the “CLIPI” could enable more personalized treatment of cutaneous lymphomas, identifying patients who may benefit from intensified treatment.Featured ArticlesMarstacimab prophylaxis in hemophilia A/B without inhibitors: results from the phase 3 BASIS trialMatched donor allogeneic CAR-T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletionA new prognostic index (CLIPI) for advanced cutaneous lymphoma enables precise patient risk stratification

Evening Prayer (people with lymphoma, Hodgkin and non-Hodgkin)  #prayer #pray #eveningprayer #jesus #god #holyspirit #aimingforjesus #healing #bible #love #peace #lymphoma #hodgkin #nonhodgkin Thank you for listening, our heart's prayer is for you and I to walk daily with Jesus, our joy and peace aimingforjesus.com YouTube Channel https://www.youtube.com/@aimingforjesus5346 Instagram https://www.instagram.com/aiming_for_jesus/ Threads https://www.threads.com/@aiming_for_jesus X https://x.com/AimingForJesus Tik Tok https://www.tiktok.com/@aiming.for.jesus

Today's episode highlights breast health concerns and educates women to make informed choices, as Dr. Robert Whitfield sits down with Dr. Alan Gonzalez, a fellow expert in plastic surgery. They break down what BII is, talk through common symptoms, and dive into complications like capsular contracture and even rare cases of lymphoma. The doctors walk listeners through the different surgical options for removing implants, including total capsulectomy, and discuss alternatives such as fat transfer for those considering a different look after explantation. They don't shy away from discussing the emotional and physical challenges that can come with implant removal, and the conversation is one all women need to hear. Bio: Dr. Alan Gonzalez Dr. Alan González is a leading plastic surgeon in Colombia and Latin America, with over 25 years of experience and more than 20,000 aesthetic and reconstructive procedures performed. Known for combining cutting-edge surgical techniques with a focus on minimal scarring and fast recovery, he is dedicated to enhancing patient well-being through thoughtful, results-driven care. Dr. González is also a global speaker, researcher, and media contributor, and currently leads multidisciplinary research on the link between breast implants and ASIA syndrome. He is affiliated with several international surgical societies and serves as the scientific director of Care Me 360 Institute. (https://careme360.com/) Learn more about Dr. González at dralangonzalez.com (https://dralangonzalez.com/)and connect with him on Instagram (https://www.instagram.com/dralangonzalez/) or LinkedIn (https://www.linkedin.com/in/alan-gonzalez-md/). Show Highlights: Dr. Gonzalez's Background & Early Experience (00:01:09) Dr. Gonzalez shares his medical background, early views on implants, and initial belief in their safety. Recognition of Implant Complications (00:04:25) *Discovering complications like lymphoma, chronic inflammation, and the shift in understanding implant risks *Capsular Contracture & Surgical Approaches (00:10:11) *Capsular contracture, historical surgical practices, and the evolution of implant placement techniques *Patient Symptoms & Chronic Inflammation (00:14:11) Normalization of symptoms, and the importance of recognizing chronic inflammation from implants Capsulectomy Techniques & Cancer Concerns (00:17:26) Debate on total vs. en bloc capsulectomy, surgical safety, and handling abnormal capsule findings Case Study: Lymphoma & Pathology Challenges (00:19:53) Dr. Whitfield shares a case of rare lymphoma, challenges in diagnosis, and the importance of surgical expertise Patient Education & Informed Choices (00:25:47) Educating patients, the need for transparency, and the importance of understanding all surgical options *Alternatives to Implants: Fat Transfer & Lifts (00:27:20) *Non-implant options like fat transfer and breast lifts, and the importance of individualized patient care *Surgeon Expertise & Surgical Evolution (00:44:07) *Importance of expert surgeons, reconstructive techniques without implants, and the evolution of breast surgery Links and Resources Let's Connect Podcast: https://podcasts.apple.com/gb/podcast/breast-implant-illness/id1678143554 Spotify: https://open.spotify.com/show/1SPDripbluZKYsC0rwrBdb?si=23ea2cd9f6734667 TikTok: https://www.tiktok.com/@drrobertwhitfield?t=8oQyjO25X5i&r=1 IG: https://www.instagram.com/breastimplantillnessexpert/ FB: https://www.facebook.com/DrRobertWhitfield Linkedin: https://www.linkedin.com/in/dr-robert-whitfield-md-50775b10/ X: https://x.com/rob_whitfieldmd Read this article - https://www.breastcancer.org/treatment/surgery/breast-reconstruction/types/implant-reconstruction/illness/breast-implant-illness Shop: https://drrobssolutions.com SHARP: https://www.harp.health NVISN Labs - https://nvisnlabs.com/ Get access to Dr. Rob's Favorite Products below: Danger Coffee - Use our link for mold free coffee - https://dangercoffee.com/pages/mold-free-coffee?ref=ztvhyjg JASPR Air Purifier - Use code DRROB for the Jaspr Air Purifier - https://jaspr.co/ Echo Water - Get high quality water with our code DRROB10 - https://echowater.com/ BallancerPro - Use code DRROBVIP for the world's leader in lymphatic drainage technology - https://ballancerpro.com Ultrahuman - Use code WHITFIELD10 for the most accurate wearable - https://www.ultrahuman.com/ring/buy/us/?affiliateCode=drwhitfield

In this week's episode, we'll learn more about relationships between Epstein-Barr virus genomic variants and human diseases, including hematological malignancies; the presence and timing of somatic GATA1 mutations and their relationship to a Down syndrome-specific form of leukemia; and new definitions for high-risk multiple myeloma that emphasize the presence of two or more high-risk cytogenetic abnormalities.Featured Articles:Association of Epstein-Barr virus genomic alterations with human pathologiesClinical significance of preleukemic somatic GATA1 mutations in children with Down syndromeBiallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma

Dr. Jonathan Sessler, Professor of Chemistry at The University of Texas at Austin, is no stranger to taking an active role in directing his own path. Being a three-time Hodgkin's Lymphoma cancer survivor, Dr. Sessler's battle with cancer inspired him to research porphyrins, a class of pigments which are essential for biological processes like oxygen transport. On this exciting episode of Let's Talk Chemistry edited by Jasmine Winter, hosts Neel Youts and Jason Lu discuss our interview with Dr. Jonathan Sessler, from unique upbringing growing up in a family of scientists to his pioneering work on creating expanded porphyrins called texaphyrins and co-founding Pharmacyclics, a successful biopharmaceutical company primarily focused on the development of cancer therapies. We hope you enjoy!

Heather Brooker hosts your Friday morning Wake Up Call. Former counterterrorism coordinator for DHS and current ABC News consultant John Cohen opens the show talking about political violence and why it's a ‘both sides' problem. The House Whisperer Dean Sharp joins the show to talk about proposed ‘zero zero' rules and why they are becoming a hot topic in California. Bloomberg Media's Courtney Donohoe shares the latest in business and Wall Street.

Millions of Americans are part of the Sandwich Generation, people who are raising children while also caring for aging parents. For KFI's Heather Brooker, that role became deeply personal when her mother, Barbara, faced lymphoma not once, but twice. For National Blood Cancer Awareness Month, Heather shares her family's story of cancer survival, resilience, and the everyday challenges of balancing life in the middle. With insights from a City of Hope oncologist and a family therapist, this conversation sheds light on the stress, strength, and hope that define the Sandwich Generation.

In this week's episode we'll learn about Azacitidine in VEXAS syndrome. Treatment can provide responses in patients with this complex autoinflammatory disorder. But relapse rates were high, so long-term therapy may be required to maintain disease control. After that: A step forward in precision blood matching. High-throughput array genotyping enables extended matching to reduce antibody formation. The results show the potential for reducing harm in regularly transfused patients. Finally, identifying a new vulnerability in TP53-mutated AML. Loss of the tumor suppressor BAP1 defines a unique subtype of TP53-mutated de novo AML. BAP1 loss also confers sensitivity to BCL-xL inhibitors in vivo, opening a new therapeutic avenue.Featured ArticlesEfficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from FRENVEXArray genotyping of transfusion-relevant blood cell antigens in 6946 ancestrally diverse study participantsLoss of BAP1 defines a unique subtype of TP53-mutated de novo AML and confers sensitivity to BCL-xL inhibitors

In this Review Series episode, Associate Editor Dr. Hervé Dombret speaks with Dr. Mark Litzow about the latest immunotherapy advances for Acute Lymphoblastic Leukemia (ALL). The discussion highlights innovative treatments like blinatumomab and inotuzumab, which are showing remarkable success in clinical trials, including an 85% three-year survival rate and over 90% complete remission in elderly patients. Researchers are focusing on reducing chemotherapy intensity, developing personalized treatment approaches, and identifying optimal immunotherapy strategies for different ALL subtypes. The conversation underscores a promising shift towards more targeted, less toxic treatments that could significantly improve patient outcomes across various age groups and disease characteristics. These emerging therapies represent a potential paradigm shift in ALL treatment, offering hope for more effective and less aggressive therapeutic interventions.Read Dr. Litzow's paper “Incorporation of immunotherapy into frontline treatment for adults with B-cell precursor acute lymphoblastic leukemia” or find the whole review series on acute lymphoblastic leukemia in volume 145 issue 14 of Blood Journal. 

In this episode of Everyday Oral Surgery, we continue our Heme Series on all things blood-related by discussing lymphomas and multiple myeloma. Joining Dr. Stucki on the podcast again, to share a wealth of knowledge, are Drs. Andrew Jenzer and Maxwell Lloyd. They delve into a discussion on the basics of lymphomas, dissecting the two categories of Hodgkin's and non-Hodgkin lymphoma, and get into the diagnosis and presenting symptoms, stages, risk stratification, and treatments of each category. Next, they touch on what Tumor Lysis Syndrome (TLS) is and dive into a broad discussion on multiple myeloma. Dr. Lloyd breaks down the spectrum of this disease, including the signs and symptoms, testing and diagnostics, and explains that there is no cure for the disease. He also expands on the various treatments and management regimens available. To hear more, including thoughts on how to improve communication between collaborating teams, be sure not to miss out on today's episode. Thanks for tuning in!Key Points From This Episode:Introduction to today's topic as we continue our Heme Series.Dr. Lloyd talks us through lymphoma basics.Dr. Jenzer unpacks the presenting symptoms of the Hodgkin lymphoma category.Stages and risk stratification that constantly evolve: Ann Arbor Staging System. Treatment of lymphoma: thinking broadly, as regimens seem to be changing quickly.  We discuss the same aspects, but of the non-Hodgkin lymphoma category.Dr. Lloyd dives broadly into the chemotherapy regimen options for non-Hodgkin lymphoma.He explains a double-hit lymphoma and the associated treatment.We discuss Tumor Lysis Syndrome (TLS).Dr. Jenzer explains what multiple myelomas are. Dr. Lloyd further unpacks the spectrum of this disease (multiple myeloma).Signs and symptoms of multiple myeloma.An explanation for the lack of a cure for multiple myeloma.Testing and diagnostics of multiple myelomaDr. Lloyd broadly delves into the different types of medications and treatments used in managing multiple myeloma.He touches on some of the side effects of the medications.Big takeaway points from today's discussion.Dr. Lloyd's thoughts on how we can improve communication between collaborating teams.Final thoughts and recommendations to listeners.Links Mentioned in Today's Episode:Dr. Andrew Jenzer Email — andrew.jenzer@duke.edu Dr. Maxwell Lloyd — https://connects.catalyst.harvard.edu/Profiles/display/Person/192727 AAOMS — https://aaoms.org/education-meetings/meetings/ NCCN Guidelines — https://www.nccn.org/guidelines/category_1 Ann Arbor Staging System — https://www.ncbi.nlm.nih.gov/books/NBK65726.23/table/CDR0000062933__557/?report=objectonly St. Louis Course — https://stlomfsreview.com/ Everyday Oral Surgery Website — https://www.everydayoralsurgery.com/ Everyday Oral Surgery on Instagram — https://www.instagram.com/everydayoralsurgery/ Everyday Oral Surgery on Facebook — https://www.facebook.com/EverydayOralSurgery/Dr. Grant Stucki Email — grantstucki@gmail.comDr. Grant Stucki Phone — 720-441-6059

In this week's episode we'll learn about persistent changes in immune profiles in patients who have had diffuse large B-cell lymphoma, or DLBCL, and other cancers; that plasminogen activation and plasmin activity do not appear to play a role in routine physiological prevention of venous thromboembolism, or VTE; and about a novel mechanism that makes hematological malignancies carrying epigenetic mutations susceptible to PARP inhibitors.Featured Articles:Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatmentPlasminogen activation and plasmin activity are not required to prevent venous thrombosis/thromboembolismTransposable elements as novel therapeutic targets for PARPi-induced synthetic lethality in PcG-mutated blood cancer

Mycosis fungoides - a term that is both misleading and redundant. It represents just one aspect of the often complex world of cutaneous T-cell lymphoma. When should clinicians suspect cutaneous T-cell lymphoma? How is it accurately diagnosed? What treatment options are available? In this episode, dermatologists Dr Friyana Bhabha and A/Prof Aaron Robinson provide expert insights into these questions.See omnystudio.com/listener for privacy information.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Sairah Ahmed, MD CAR T-cell therapies have helped transform the treatment of aggressive lymphomas, but could they also change the game for slower-growing, harder-to-treat diseases like marginal zone lymphoma? Based on new data from the TRANSCEND FL study, liso-cel achieved a 95 percent overall response rate and sustained 24-month progression-free survival in relapsed/refractory marginal zone lymphoma. Here with Dr. Charles Turck to share the key efficacy and safety findings is Dr. Sairah Ahmed, Professor in the Department of Lymphoma and Myeloma and CAR T Program Director at MD Anderson Cancer Center.

In this week's episode, we'll learn about how TET2 is often mutated in myeloid malignancies and clonal hematopoiesis. In new work, expansion of Tet2-mutant HSPCs was dependent on Ncoa4, the cargo receptor mediating ferritinophagy. We'll iron out the implications. After that: a double-oh-seven license to kill in T-cell leukemia/lymphoma. WU-CART-007 is an off-the-shelf CAR T product with manageable safety and encouraging efficacy. With further work, it could become a new option for patients in urgent need of therapy. Finally: a comprehensive genetic study of classical Hodgkin lymphoma using circulating tumor DNA. This new research provides novel and complex insights on genetic subtypes, prognostic biomarkers, neoantigens in the disease environment, and more.Featured Articles:An in vivo barcoded CRISPR-Cas9 screen identifies Ncoa4-mediated ferritinophagy as a dependence in Tet2-deficient hematopoiesisPhase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignanciesA comprehensive genetic study of classic Hodgkin lymphoma using circulating tumor DNA

In this episode, Dr Brad Kahl and Dr Noopur Raje discuss the recent advances and emerging data for CAR T-cell therapy in lymphomas and multiple myeloma including the latest evidence from long-term clinical trial follow-up and real-world data, plus new data with CAR T-cell therapies in new lymphoma settings and novel CAR T-cell therapies currently under development for multiple myeloma.LymphomasDLBCL: Real-world outcomes post axi-cel, CAR T vs autologous HSCTFL: Tisa-cel (ELARA), axi-cel (ZUMA-5)MZL: Liso-cel (TRANSCEND FL)MCL: Real-world outcomes post brexu-celCLL: Liso-cel (TRANSCEND CLL 004)Multiple MyelomaCilta-cel (CARTITUDE-1)Anito-cel (iMMagine-1)GC012FArlo-celBMS-986453TriPRIL Presenters:Brad Kahl, MDProfessor of MedicineWashington University St Louis, MissouriNoopur Raje, MD Director, Center for Multiple MyelomaMassachusetts General Hospital Cancer CenterProfessor of MedicineHarvard Medical SchoolBoston, Massachusetts Content based on an online CME program supported by an independent educational grant from Bristol Myers Squibb.Link to full program: https://bit.ly/3ViR62V

To the people who read her blog and attended her church, Amanda C. Riley was a beautiful, young wife and mother who managed to live her life with hope and faith even as she was dying of Hodgkin's Lymphoma. But who was the real Amanda?  The story of how this beguiling woman deceived and betrayed countless supporters, including many of her closest friends, is so compelling, Charlie Webster's 2023 “Scamanda” was the most downloaded and shared podcast, world-wide, on Apple that year, since sparking a 2025 Hulu docuseries. In Part 1 of this fascinating podcast, we first introduce you to the carefully-crafted persona Amanda showed to the world, then take you behind the scenes to meet the real Amanda C. Riley. Join us as we walk through the events that led to one of the most infamous and morally unethical scams ever documented… and ultimately resulted in a first-ever case of its kind for the FBI.  Listen (and follow!) on your favorite app or Scandal Water Podcast YouTube channel.  Thank you to listener Rebekah for her ongoing support on Buymeacoffee.com!   How to support Scandal Water: Rate, review and subscribe! Send your shoutouts to scandalwaterpodcast@gmail.com. Become a member on patreon.com/ScandalWaterPodcast or buymeacoffee.com/scandalwaterpod – which will also grant you access to fabulous bonus content! #Scamanda #Scam #ScammySeptember #TeamAmanda #AmandaCRiley #HodgkinsLymphoma CharlieWebster #Podcaster #Podcast #HuluDocumentary #Season5 #ScandalWaterPodcast 

Blood Editor, Dr. Thomas Coates interviews Dr. Emanuele Angelucci on his paper, "How I manage iron overload in the hematopoietic cell transplantation setting" which is featured in Blood's "How I Treat Series on Iron Overload in Hematologic Disorders". See the full How I Treat series in volume 145 issue 4 of Blood. 

In this week's episode we'll learn about targeting NPM1 in acute myeloid leukemia. Researchers report the first clinical evidence of a menin inhibitor inducing complete remissions in AML with a NPM1 mutation. This validates NPM1 as a new therapeutic target in AML, alongside FLT3, IDH1/2, and KMT2A. Also on the podcast: targeting CD137 to prevent graft-versus-host disease. In nonhuman primates, a single dose of a CD137 antibody-drug conjugate provided long-term protection, with one important caveat: the potential for viral reactivation.Featured Articles: Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 studyA single dose of a CD137 antibody–drug conjugate protects rhesus macaque allogeneic HCT recipients against acute GVHD

In this week's episode we'll learn about how by combining PET response with circulating tumor DNA, or  ctDNA, in newly treated patients with follicular lymphoma, investigators identify those patients likely to progress within 24 months of initial treatment, also known as POD24. After that: Immune hotspots in aplastic anemia. These newly identified hotspots potentially represent sites in the bone marrow where the active immune response takes place, driving the destruction of hematopoietic stem and progenitor cells. Finally, allogeneic transplantation for Hodgkin lymphoma in the checkpoint inhibitor era. In a large, retrospective study, patients with prior checkpoint inhibitor exposure had remarkable outcomes, particularly when post-transplant cyclophosphamide was used.Featured Articles: Combined PET and ctDNA response as predictors of POD24 for follicular lymphoma after first-line induction treatmentImaging Mass Cytometry Reveals the Order of Events in the Pathogenesis of Immune-Mediated Aplastic AnemiaOutcomes of Allogeneic HCT in Hodgkin Lymphoma in the Era of Checkpoint Inhibitors: A Joint CIBMTR and EBMT Analysis

In this episode of Blood Cancer Talks, we have Dr. Adrian Minson from the Peter MacCallum Cancer Centre to discuss the latest developments in lymphoma presented at the recent EHA and ICML meetings in June 2025. The episode focuses primarily on the emerging role of bispecific antibodies in various combinations and treatment settings for diffuse large B-cell lymphoma (DLBCL).Key Clinical Trials Discussed1. POLARGO Trial - Polatuzumab + R-GemOx vs R-GemOx in R/R DLBCL2. SUNMO Trial - Mosunetuzumab + Polatuzumab vs R-GemOx in R/R DLBCL3. STARGLO Trial - Glofitamab + GemOx vs R-GemOx in R/R DLBCL (2-Year Update)4. EPCORE NHL-5 & NHL-7 - Epcoritamab Combinations in Frontline DLBCL5. EPCOR-RICE - Epcoritamab + R-ICE in Transplant-Eligible R/R DLBCL6. LOTIS-7 Trial - Loncastuximab + Glofitamab in R/R DLBCL7. Additional Studies Mentioned:R-Pola-Glo Frail StudyDLBCL Classification

In this week's episode, we'll learn more about how exogenous CD19 stimulation affects CAR T-cell persistence in B-cell acute lymphoblastic leukemia treated with CD19 CAR T-cell therapy; new algorithms that incorporate sequential rapid immune-assays, intended to improve diagnosis of heparin-induced thrombocytopenia, and resource-adaptive survival prediction models to help guide management of patients with chronic myelomonocytic leukemia.Featured Articles:Outcomes of PLAT-02 and PLAT-03: evaluating CD19 CAR T-cell therapy and CD19-expressing T-APC support in pediatric B-ALLSequential combinations of rapid immunoassays for prompt recognition of heparin-induced thrombocytopeniaBLAST: a globally applicable and molecularly versatile survival model for chronic myelomonocytic leukemia

Today's guest is Rebecca Thomas, also known as "Giddy Up" within her cancer community, due to her love of horses and her inspiring journey. Rebecca was diagnosed with Hodgkin's Lymphoma at age 18 and has been a survivor for 33 years now, including a breast cancer diagnosis in 2019. She embodies living a meaningful, vibrant life as a long term survivor.We talk about how diagnosis as a young adult shapes the rest of your life, the wonder of the human body and what it can do, the healing power of horses, the impact of long term survivorship, finding community, and so much more!! Resources:Rebecca's Facebook: Rebecca ThomasEpic Experience: https://www.epicexperience.org/Follow:Follow me: https://www.instagram.com/melissagrosboll/My website: https://melissagrosboll.comEmail me: drmelissagrosboll@gmail.com

Our guest this week is another hardcore Huntington Beach OG. A former pro snowboarder turned entrepreneur, he's had an impressive run across multiple industries over the past 20 years. From working as a physical therapist to repping for O'Neill Snow, his hustle never stopped. In 2004, after his cousin Brandon McGuinness (RIP) was diagnosed with Hodgkin's Lymphoma, he co-founded the F C Cancer Foundation—a 501(c)(3) nonprofit focused on early detection and prevention. As Executive Director and CEO, he's dedicated his life to pushing the Foundation's mission forward. We're stoked to hear about his journey, the legacy he's building, and the future he's shaping. Please welcome to the show, Mr. John "MUGS" McGuinness.

In this episode, Associate Blood editor Dr. Selina Luger leads a discussion with Drs. Courtney DiNardo, Eunice Wang, Andrew Wei and Gail Roboz about the advances in treatment options for Acute Myeloid Leukemia (AML). See the full How I Treat series on Acute Myeloid Leukemia in volume 145 issue 12 of Blood journal.

In this week's episode, we'll learn more about the effects of daratumumab maintenance on minimal residual disease in patients with newly diagnosed, transplant-eligible multiple myeloma; the role of neutrophils in the pathophysiology of myeloproliferative neoplasms; and a genome-wide association study that identified novel genetic loci associated with the risk of heavy menstrual bleeding.Featured ArticlesDaratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease resultsDefective neutrophil clearance in JAK2^V617F myeloproliferative neoplasms drives myelofibrosis via immune checkpoint CD24Genome-wide meta-analysis of heavy menstrual bleeding reveals 36 risk loci

My guest today is Valerie David. NYC-based performer/playwright Valerie David wrote and performs her award-winning solo show, The Pink Hulk: One Woman's Journey to Find the Superhero Within, to inspire and empower others through the courage and inner strength she found to become a 3-time cancer survivor—Stage III Non-Hodgkin's Lymphoma, Stage II Breast Cancer, and Stage IV Metastatic Breast Cancer. Through medical advancements, Valerie currently has no evidence of disease. The Pink Hulk has been accepted into over 60 different play festivals and 25 different cities worldwide, including England, Sweden, Iceland, and Finland, garnering multiple awards. Valerie and her show have impacted audiences since its 2016 debut with its motto: NEVER GIVE UP HOPE! She received the President's Lifetime Achievement Award: Resilience in Action for her patient advocacy work from the Biden administration. Her second award-winning solo show, Baggage From BaghDAD: Becoming My Father's Daughter, is about her Middle Eastern Jewish family's true inspirational journey of being forced to flee from religious persecution during the 1941 “Farhud” pogrom in Baghdad. It is the story of Valerie's father and his family's struggle to transcend their harrowing past and build a new home in America. It celebrates the resiliency of the human spirit and finds humor, even in the darkest of times. In this episode we discuss cancer, self-advocacy, speaking your truth, healing and performance.Website: https://pinkhulkplay.com/LinkedIn - https://www.linkedin.com/in/valeriedavid/FB - https://www.facebook.com/pinkhulkplay/ https://www.facebook.com/valerie.david.96558/IG - https://www.instagram.com/valeriedavid_pinkhulkplay/YouTube - https://www.youtube.com/channel/UCyDPITlLi5AwO_1beXL2Ogw https://www.youtube.com/channel/UCXRTfJ7EdCBEjlhsZw3bI-wIn this episode you will learn:1. The power of laughter to help get through immense challenges.2. The importance of finding and using your voice to advocate for yourself .3. How empathy can help lead to opening your heart and understanding others. “I think what inspired me was the fact that I had two different cancers. So in breast cancer, according to the American Cancer Society, less than 1% of all men get breast cancer."- 00:07:35“If you're not in perpetual motion Then there's something wrong and I think that's the opposite because you need time to take a break You need time for yourself." - 00:25:46“I think it taught me to be in the now, in the present moment what can I do now and not to worry, look too much into the future because you don't, you're only in control of what you can do now.” 00:47:33

In this week's episode we'll learn more about enhanced transplant characteristics; targeting the JAK-STAT pathway with ruxolitinib in patients with adult-onset Still's disease and macrophage activation syndrome; and a pair of trials demonstrating lack of benefit for the anti-CD47 monoclonal antibody magrolimab in newly diagnosed acute myeloid leukemia.Featured ArticlesHeterogeneity of high-potency multilineage hematopoietic stem cells and identification of “Super” transplantabilityRuxolitinib targets JAK-STAT signaling to modulate neutrophil activation in refractory macrophage activation syndromeMagrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 studyThe ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy

In this week's episode, we'll learn about a JAK inhibitor to prevent complications of CD19-directed CAR T-cell therapy. In a phase 2 study, itacitinib was well tolerated and demonstrated promising reductions in the incidence of cytokine release syndrome and neurotoxicity. After that: investigators report direct interactions between ChAdOx1 and platelets under arterial shear conditions. Investigators say it's a novel biophysical mechanism that potentially contributes to post-vaccination arterial thrombosis. Finally, we explore lineage switch, an emerging form of acute leukemia relapse with dismal outcomes. It arises rapidly following antigen-targeted immunotherapy, highlighting the importance of advanced methods for detection and treatment.Featured Articles: Itacitinib for the prevention of IEC therapy–associated CRS: results from the 2-part phase 2 INCB 39110-211 studyShear-dependent platelet aggregation by ChAdOx1 nCoV-19 vaccine: a novel biophysical mechanism for arterial thrombosisProject EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia

Dr. Pallawi Torka of Memorial Sloan Kettering Cancer Center joins to share highlights from ASCO and EHA 2025 on the evolving landscape of B-cell lymphomas, including Hodgkin lymphoma, diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma. She offers in-depth insights on the STARGLO study and its recent ODAC review, the POLARGO trial, a rare T-cell leukemia (T-LGL) study, and new data supporting nivolumab-AVD in frontline Hodgkin lymphoma. Additional discussion includes the inMIND trial for follicular lymphoma, the growing role of ctDNA in managing DLBCL, advances in CAR-T cell therapy for CNS lymphoma, and how she is adapting treatment strategies based on favorable vs. unfavorable disease features. Check out Chadi's website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/ Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

Meet Nikki, whose bout with mono when she was younger ultimately led to a diagnosis of Hodgkin's Lymphoma as an adult.  But Nikki is one of the lucky ones - her case was not only treatable, but curable.     #unroutineinspiration

Welcome to this episode of The Oncology Brothers! Drs. Rahul and Rohit Gosain dived into the complexities of relapsed refractory diffuse large B-cell lymphoma (DLBCL) with their new series focused on challenging real-life cases. In this episode, we are joined by esteemed guests Dr. Carla Casulo from Wilmot Cancer Center and Dr. Tara Graff from Mission Cancer and Blood Center. Together, we explored the current standard of care, including R-CHOP and the role of bi-specific antibodies like epcoritamab and glofitimab. Key topics covered included: • When to use bi-specific antibodies and how to manage side effects • The importance of MRD monitoring in treatment decisions • Insights on patient management in community oncology settings • The evolving landscape of treatment options for DLBCL, including CAR-T therapy and clinical trials We also discuss practical considerations for community oncologists, including the management of cytokine release syndrome (CRS) and the role of immunoglobulin therapy in patients with low IgG levels. Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode is packed with valuable insights and expert opinions. YouTube: https://youtu.be/05ieIyAIx_8 Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and share your thoughts in the comments! Let us know if there are specific scenarios you'd like us to cover in future episodes.

Welcome to the Oncology Brothers podcast! In this episode, Drs. Rohit and Rahul Gosain dive deep into the world of diffuse large B-cell lymphoma (DLBCL), one of the most aggressive yet potentially curable lymphomas. We are joined by Dr. John Leonard, a renowned lymphoma expert from NYU Langone Cancer Center, who shares his insights on the latest data and evolving treatment landscape for DLBCL. Episode Highlights: •⁠  ⁠Understanding the initial workup for DLBCL, including the role of PET-CT and bone marrow biopsies. •⁠  ⁠The use of RCHOP and the emerging Pola-R-CHP regimen in Stage 1 and Stage 2 settings. •⁠  ⁠Discussion on the treatment options for Stage 3 and Stage 4 disease, including the impact of polatuzumab. •⁠  ⁠Insights into managing relapsed/refractory disease and the role of CAR-T therapy. •⁠  ⁠The potential shift towards outpatient CAR-T treatments and the nuances between different CAR-T options. •⁠  ⁠Exploring bispecific antibodies and their applications in treatment sequencing. YouTube: https://youtu.be/raGkPnUs9XM Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Join us as we unpack the complexities of DLBCL treatment and share valuable clinical pearls for community settings. Don't forget to subscribe for more episodes on challenging cases and the latest in oncology!

Today, on Karl and Crew, we kicked off the week with discussions about a cancer patient ministry with Phil Zielke and how to make the most of a screen-free summer with your kids, with Arlene Pellicane. First, Phil Zielke joined us to share his testimony of how he drew near to God when he was diagnosed with Stage 4B Hodgkin’s Lymphoma, and then how God placed it on his heart to start a ministry that serves cancer patients. Phil’s Friends is a ministry that provides Christ-centered support and hope to those affected by cancer. Then we had Arlene Pellicane join us to talk about the importance of parents connecting with their children by limiting their screen time. Arlene is a speaker, author, and host of the Happy Home podcast. She is also a marriage and parenting expert. Arlene has also authored several books, including “Screen Kids.” We then discussed our need for God’s grace. We were born into sin, so it is in our nature to be sinful, but when we are born again through Christ, we are renewed by God’s grace. Romans 7:18-25 affirms this, as Paul tells us that sin dwells within us and affects how we move and think without God. Only God can deliver us from sin through Jesus Christ. We also heard updates from Karl, who was broadcasting remotely from the Maranatha Bible Missionary Conference, Vacation and Retreat Center. Dr. Josh Stephens joined Karl to discuss the sovereignty and providence of God as shown throughout the book of Ruth. Dr. Stephens is the Lead Pastor of Cape Bible Church in Missouri and is also the founder and executive director of the Biblical Counseling Alliance. You can hear the highlights of today's program on the Karl and Crew Showcast. If you're looking to hear a particular segment from the show, look at the following time stamps: Gospel (Need for God) [ 05:55-17:30 ] Phil Zielke Interview (Phil's Friends Ministry) [ 44:25-55:18 ] Arlene Pellicane Interview [ 55:28-01:06:34 ] Dr. Josh Stephens (Book of Ruth breakdown) [ 30:50-43:50 ]Donate to Moody Radio: http://moodyradio.org/donateto/morningshowSee omnystudio.com/listener for privacy information.

Heather Lino's then 3 year old son James was given a double whammy in 2020 when he was first diagnosed with T Cell Acute Lymphoblastic Lymphoma in July, and then roughly one month into his treatment he was diagnosed with a Chromosomal disorder known as Ring 14 Syndrome. This disorder affects 200-250 people around the world. This affliction causes seizures and intellectual disabilities and can have other problems associated with it as well. James is now 8 years old and is living his best life possible. 

In a heartfelt conversation, Def Leppard guitarist Vivian Campbell reveals his remarkable path to beating cancer through a successful bone marrow transplant. He discusses his 13-year battle with Hodgkin's Lymphoma, the emotional impact of finding a perfect donor match, and his unwavering determination to keep performing throughout treatment. Campbell also shares updates on Def Leppard's upcoming album, his side project Last in Line, and his newfound passion for rally racing. Also on the podcast, from writing 'New York Groove' on a flight to NYC to seeing The Beatles adopt his tailor recommendations, Russ Ballard opens up about his remarkable 60-year career crafting hits for rock's biggest names. He reveals the origins of classics like 'Since You've Been Gone' and 'God Gave Rock and Roll to You,' while discussing his latest double album and philosophy that keeping active in music helps maintain youthful energy.  Catch Eddie Trunk every M-F from 3:00-5:00pm ET on Trunk Nation on SiriusXM Faction Talk Channel 103.And don't forget to follow Eddie on Twitter and Instagram!Follow the link to get your free 3-month trial of SiriusXM: http://siriusxm.com/eddietrunk Find all episodes of Trunk Nation: https://siriusxm.com/trunknation

Mike is out of town, so Jim brought in one of Third Street Barbell's most consistent and inspirational members, Josh Hajar.Josh is an emergency department nurse who faced a harrowing fight with non-Hodgkin's Lymphoma, and then suffered an injury that set back his recovery and fitness goals. When he arrived at Third Street, he was finally ready to execute a winning game plan for losing weight and getting stronger. Building on the advice he received when he first received his cancer diagnosis to “Be Positive,” Josh sets a strong example in and out of the gym.Join our Discord for free at goodcompanydiscord.com!Check out our gym (Third Street Barbell) at ThirdStreetBarbell.com https://www.thirdstreetbarbell.com/ and subscribe for updates about our apparel line at goodcompanyapparel.com https://3sb.co/! Local memberships and international fresh fits! Get early access to our NEXT DROP!Check out our podcast website: 50percentfacts.com https://www.50percentfacts.com/50% Facts is a Spreaker Prime podcast on OCN – the Obscure Celebrity Network.____Hosted by Mike Farr (@silentmikke) https://www.instagram.com/silentmikke/ and Jim McDonald (@thejimmcd). https://www.instagram.com/thejimmcd/Produced by Jim McDonaldProduction assistance by Sam McDonald and Sebastian Brambila.Theme by Aaron Moore. Show art by Joseph Manzo (@jmanzo523)Become a supporter of this podcast: https://www.spreaker.com/podcast/50-facts-with-silent-mike-jim-mcd--5538735/support.